Heidi T May1, Jeffrey L Anderson2, Deborah A Winegar3, Jeffrey Rollo4, Margery A Connelly3, James D Otvos3, Joseph B Muhlestein2. 1. Intermountain Medical Center, 5121 S Cottonwood St, Murray, UT, USA. Electronic address: heidi.may@imail.org. 2. Intermountain Medical Center, 5121 S Cottonwood St, Murray, UT, USA; University of Utah, 30 N 1900 E, Salt Lake City, UT, USA. 3. LipoScience, Laboratory Corporation of America® Holdings, 2500 Sumner Blvd, Raleigh, NC, USA. 4. Intermountain Medical Center, 5121 S Cottonwood St, Murray, UT, USA.
Abstract
BACKGROUND: HDL-C is recognized to be inversely associated with cardiovascular (CV) risk. However, attenuation of the association of HDL-C with CV risk may occur after adjustment for other lipoprotein parameters and in various disease states, especially in the setting of acute coronary syndrome (ACS). Recently, the number of HDL particles (HDL-P) has been suggested to improve CV risk prediction. METHODS AND RESULTS: Patients (n=2999) in the Intermountain Heart Collaborative Study who underwent angiography and had lipoprotein particle measurements determined by nuclear magnetic resonance (NMR) spectroscopy were studied. Multivariable Cox hazard regression was utilized to evaluate the association of HDL-C, HDL-P, and HDL-P subclasses with future major adverse CV events (MACE: death, myocardial infarction, heart failure, and stroke). Patients averaged 64±12years, 66% male, 26% diabetic, and 42% ACS. At angiography, 65% of patients were diagnosed with coronary artery disease (CAD). HDL-C and HDL-P averaged 41±13mg/dL and 28±8μmol/L, respectively. HDL-P (HR=0.903, p=0.001), but not HDL-C (HR=0.947, p=0.102) was significantly associated with MACE. In a model that included all HDL-P subclasses, both small (HR=0.862, p<0.0001) and medium (HR=0.922, p=0.020) were associated with CV risk, but not large HDL-P (HR=1.0042, p=0.185). Small HDL-P continued to be associated with all of the individual components of MACE, but not stroke. CONCLUSION: In this study of patients undergoing angiography, HDL-P was a strong, independent predictor of future MACE, with the smaller HDL-P accounting for this association.
BACKGROUND: HDL-C is recognized to be inversely associated with cardiovascular (CV) risk. However, attenuation of the association of HDL-C with CV risk may occur after adjustment for other lipoprotein parameters and in various disease states, especially in the setting of acute coronary syndrome (ACS). Recently, the number of HDL particles (HDL-P) has been suggested to improve CV risk prediction. METHODS AND RESULTS:Patients (n=2999) in the Intermountain Heart Collaborative Study who underwent angiography and had lipoprotein particle measurements determined by nuclear magnetic resonance (NMR) spectroscopy were studied. Multivariable Cox hazard regression was utilized to evaluate the association of HDL-C, HDL-P, and HDL-P subclasses with future major adverse CV events (MACE: death, myocardial infarction, heart failure, and stroke). Patients averaged 64±12years, 66% male, 26% diabetic, and 42% ACS. At angiography, 65% of patients were diagnosed with coronary artery disease (CAD). HDL-C and HDL-P averaged 41±13mg/dL and 28±8μmol/L, respectively. HDL-P (HR=0.903, p=0.001), but not HDL-C (HR=0.947, p=0.102) was significantly associated with MACE. In a model that included all HDL-P subclasses, both small (HR=0.862, p<0.0001) and medium (HR=0.922, p=0.020) were associated with CV risk, but not large HDL-P (HR=1.0042, p=0.185). Small HDL-P continued to be associated with all of the individual components of MACE, but not stroke. CONCLUSION: In this study of patients undergoing angiography, HDL-P was a strong, independent predictor of future MACE, with the smaller HDL-P accounting for this association.
Authors: Laura A McGuinn; Alexandra Schneider; Robert W McGarrah; Cavin Ward-Caviness; Lucas M Neas; Qian Di; Joel Schwartz; Elizabeth R Hauser; William E Kraus; Wayne E Cascio; David Diaz-Sanchez; Robert B Devlin Journal: Environ Int Date: 2018-11-13 Impact factor: 9.621
Authors: Nasir H Bhanpuri; Sarah J Hallberg; Paul T Williams; Amy L McKenzie; Kevin D Ballard; Wayne W Campbell; James P McCarter; Stephen D Phinney; Jeff S Volek Journal: Cardiovasc Diabetol Date: 2018-05-01 Impact factor: 9.951